The British Generic Manufacturers Association (BGMA) has welcomed Tim de Gavre as its new chair, a role he will hold for the next two years.
Gavre will replace Peter Ballard, who will serve a further year as vice-chair of the association, which is the representative organisation for generic medicine manufacturers in the UK.
A former chair of the British Biosimilars Association (BBA), the sister association to the BGMA, Gavre is Head of Sandoz UK. Gavre has worked for Sandoz since 2010 holding a series of leadership roles in Biosimilars and Generics.
Prior to joining Sandoz, Gavre worked as a consultant at McKinsey & Company and in healthcare venture capital with Frazier Healthcare Ventures. He also holds an MBA from The Wharton School and a BA from Princeton University.
Tim de Gavre, said: “It is a huge honour to be asked to be the association’s chair for the next two years. Generics and biosimilars save the NHS over £13 billion on an annual basis, which not only releases NHS money for investment in new medicines but also increases accessibility as more patients can be treated for less.”
“During my tenure as Chair of the BGMA, I want to find ways to support the NHS to better utilise generic medicines, while creating a more reliable and sustainable environment for manufacturers.”
“The next two years promise to be critical with the introduction of the Falsified Medicines Directive and BREXIT both taking place in early 2019. I look forward to working with government, the NHS and other members of the BGMA to ensure the association’s voice remains strong and that generics and biosimilars are recognised for the value that they bring to the UK,” Gavre concluded.
